FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100212498> ?p ?o ?g. }

• W3100212498 endingPage "3" @default.
• W3100212498 startingPage "1" @default.
• W3100212498 abstract "Objective Mixed dyslipidemia is characterized by elevated cholesterol and triglycerides. Indians have high prevalence of this pattern. The aim of present study was to evaluate the effects of rosuvastatin and in combination with fenofibrate or omega-3-FAs on lipids and hsCRP. Methods This was an open-label randomized study. Patients were allocated to low-dose rosuvastatin(R), rosuvastatin plus fenofibrate (RF) or rosuvastatin plus omega-3-FA(RO). At 6-weeks and 12-weeks follow-up, lipid lowering effect and change in hsCRP was studied. Results The study involved 105 participants (M/F=68/37) with a mean age of 57±13 years. At end of 6 and 12-weeks, there was significant reduction in TC, LDL-C, TG and hsCRP in all treatment groups, but increase in HDL-C became significant at 12-weeks. Percentage reduction in TC was 21%vs17%vs23% at 6-weeks and 31%vs37%vs35% at 12-weeks in group R, RF and RO, respectively. At 12-weeks, reduction in LDL-C was 22% in R vs 45% in RF vs 18% in RO and increase in HDL-C was 3.8% in R vs 7.6% in RF vs 15.8% in RO. Percentage reduction in triglycerides was 18%vs31% vs30% at 6 weeks and 23%vs52%vs51% at 12-weeks. Conclusion The mixed dyslipidemic patients responded well in terms of significant reduction in TC, LDL-C, and improving HDL-C and inflammation across all study groups. However, combination of low-dose-rosuvastatin plus fenofibrate or omega-3-FAs had more potent effect in reducing triglycerides and also in percentage increase in HDL-C, when compared with rosuvastatin alone. Omega-3 FAs, therefore, seem to be an attractive alternative to fibrates in patients with mixed dyslipidemia." @default.
• W3100212498 created "2020-11-23" @default.
• W3100212498 creator A5022054897 @default.
• W3100212498 creator A5034037969 @default.
• W3100212498 creator A5038330031 @default.
• W3100212498 creator A5068372503 @default.
• W3100212498 creator A5077025243 @default.
• W3100212498 date "2020-10-01" @default.
• W3100212498 modified "2023-09-26" @default.
• W3100212498 title "THE EFFECTS OF LOW-DOSE ROSUVASTATIN ALONE OR IN COMBINATION WITH FENOFIBRATE OR OMEGA 3 FATTY ACIDS IN MIXED DYSLIPIDEMIA" @default.
• W3100212498 cites W1971657342 @default.
• W3100212498 cites W1988048988 @default.
• W3100212498 cites W1990166147 @default.
• W3100212498 cites W1996809717 @default.
• W3100212498 cites W1999356575 @default.
• W3100212498 cites W2037017072 @default.
• W3100212498 cites W2044046404 @default.
• W3100212498 cites W2057681949 @default.
• W3100212498 cites W2058709767 @default.
• W3100212498 cites W2060308588 @default.
• W3100212498 cites W2080208126 @default.
• W3100212498 cites W2081721069 @default.
• W3100212498 cites W2106340207 @default.
• W3100212498 cites W2125628785 @default.
• W3100212498 cites W2128678876 @default.
• W3100212498 cites W2132010550 @default.
• W3100212498 cites W2132317196 @default.
• W3100212498 cites W2142347023 @default.
• W3100212498 cites W2144181696 @default.
• W3100212498 cites W2147176408 @default.
• W3100212498 cites W2152425011 @default.
• W3100212498 cites W2163292437 @default.
• W3100212498 cites W2899669642 @default.
• W3100212498 cites W4211051145 @default.
• W3100212498 cites W4238251256 @default.
• W3100212498 doi "https://doi.org/10.36106/ijsr/1301137" @default.
• W3100212498 hasPublicationYear "2020" @default.
• W3100212498 type Work @default.
• W3100212498 sameAs 3100212498 @default.
• W3100212498 citedByCount "0" @default.
• W3100212498 crossrefType "journal-article" @default.
• W3100212498 hasAuthorship W3100212498A5022054897 @default.
• W3100212498 hasAuthorship W3100212498A5034037969 @default.
• W3100212498 hasAuthorship W3100212498A5038330031 @default.
• W3100212498 hasAuthorship W3100212498A5068372503 @default.
• W3100212498 hasAuthorship W3100212498A5077025243 @default.
• W3100212498 hasBestOaLocation W31002124981 @default.
• W3100212498 hasConcept C126322002 @default.
• W3100212498 hasConcept C134018914 @default.
• W3100212498 hasConcept C2778096610 @default.
• W3100212498 hasConcept C2778110834 @default.
• W3100212498 hasConcept C2778163477 @default.
• W3100212498 hasConcept C2778270857 @default.
• W3100212498 hasConcept C2780499067 @default.
• W3100212498 hasConcept C2908737378 @default.
• W3100212498 hasConcept C511355011 @default.
• W3100212498 hasConcept C71924100 @default.
• W3100212498 hasConcept C90924648 @default.
• W3100212498 hasConceptScore W3100212498C126322002 @default.
• W3100212498 hasConceptScore W3100212498C134018914 @default.
• W3100212498 hasConceptScore W3100212498C2778096610 @default.
• W3100212498 hasConceptScore W3100212498C2778110834 @default.
• W3100212498 hasConceptScore W3100212498C2778163477 @default.
• W3100212498 hasConceptScore W3100212498C2778270857 @default.
• W3100212498 hasConceptScore W3100212498C2780499067 @default.
• W3100212498 hasConceptScore W3100212498C2908737378 @default.
• W3100212498 hasConceptScore W3100212498C511355011 @default.
• W3100212498 hasConceptScore W3100212498C71924100 @default.
• W3100212498 hasConceptScore W3100212498C90924648 @default.
• W3100212498 hasLocation W31002124981 @default.
• W3100212498 hasOpenAccess W3100212498 @default.
• W3100212498 hasPrimaryLocation W31002124981 @default.
• W3100212498 hasRelatedWork W1677620550 @default.
• W3100212498 hasRelatedWork W2036127398 @default.
• W3100212498 hasRelatedWork W2138021130 @default.
• W3100212498 hasRelatedWork W2477189336 @default.
• W3100212498 hasRelatedWork W2531772600 @default.
• W3100212498 hasRelatedWork W2891615092 @default.
• W3100212498 hasRelatedWork W2899078735 @default.
• W3100212498 hasRelatedWork W3100212498 @default.
• W3100212498 hasRelatedWork W4214643402 @default.
• W3100212498 hasRelatedWork W4307328920 @default.
• W3100212498 isParatext "false" @default.
• W3100212498 isRetracted "false" @default.
• W3100212498 magId "3100212498" @default.
• W3100212498 workType "article" @default.